Outcome of Board Meeting - 15052026
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 17.4 pts more than Nifty Smallcap 250 and 16.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gland Pharma Limited's Board approved audited consolidated financial results for FY ended March 31, 2026. The company reported revenue from operations of Rs. 64,306.50 million, up 14.5% year-over-year from Rs. 56,165.04 million. Profit after tax (PAT) stood at Rs. 4,372.64 million, representing 20.1% growth compared to Rs. 3,641.32 million in the previous year. Basic EPS improved significantly to Rs. 62.35 per share from Rs. 42.40. An exceptional item of Rs. 243.46 million was recorded for gratuity and leave liability due to new Indian Labour Codes effective November 2025. The Board recommended a final dividend of Rs. 20 per equity share (2000% on face value of Rs. 1). Statutory auditors Deloitte Haskins & Sells issued an unmodified opinion on the annual financial statements.
Gland Pharma delivered strong earnings growth with PAT up 20% and EPS up 47%, signaling operational strength. The clean audit opinion and healthy dividend payout are positive for shareholder returns. However, the exceptional charge from new labour codes may have temporarily impacted profitability.